GH – Guardant Health, Inc.
Guardant Health, Inc.GH
$47.65Name : Guardant Health, Inc.
Sector : Healthcare
Industry: Diagnostics & Research
Mark. Cap: $5,887,395,840.00
EPSttm : -4.28
Guardant Health, Inc.
$47.65
1.26%$0.61Float Short %
6.26
Margin Of Safety %
Put/Call OI Ratio
2.08
EPS Next Q Diff
0.32
EPS Last/This Y
2.27
EPS This/Next Y
-0.01
Price
47.66
Target Price
46
Analyst Recom
1.44
Performance Q
132.33
Relative Volume
0.71
Beta
1.34
Ticker: GH
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2024-12-30 | GH | 30.57 | 1.28 | 0.13 | 34237 |
| 2024-12-31 | GH | 30.56 | 1.25 | 0.08 | 34538 |
| 2025-01-02 | GH | 31.74 | 1.25 | 0.09 | 34590 |
| 2025-01-03 | GH | 33.73 | 1.22 | 0.38 | 34996 |
| 2025-01-06 | GH | 35.89 | 1.24 | 0.63 | 35373 |
| 2025-01-07 | GH | 36.17 | 1.30 | 2.38 | 37035 |
| 2025-01-08 | GH | 36.59 | 1.34 | 0.50 | 38151 |
| 2025-01-09 | GH | 36.59 | 1.34 | 0.50 | 38151 |
| 2025-01-10 | GH | 36.71 | 1.40 | 0.88 | 38427 |
| 2025-01-13 | GH | 38.12 | 1.36 | 1.14 | 39709 |
| 2025-01-14 | GH | 37.48 | 1.37 | 5.63 | 40246 |
| 2025-01-15 | GH | 37.54 | 1.51 | 5.59 | 42970 |
| 2025-01-16 | GH | 37.34 | 1.40 | 0.23 | 41135 |
| 2025-01-17 | GH | 36.63 | 1.41 | 2.01 | 41096 |
| 2025-01-20 | GH | 36.66 | 1.41 | 1.75 | 41096 |
| 2025-01-21 | GH | 45.11 | 2.44 | 0.17 | 25564 |
| 2025-01-22 | GH | 47.18 | 2.32 | 0.42 | 26645 |
| 2025-01-23 | GH | 48.62 | 1.92 | 0.32 | 30582 |
| 2025-01-24 | GH | 47.23 | 1.86 | 4.79 | 31039 |
| 2025-01-27 | GH | 47 | 1.95 | 2.88 | 32485 |
| 2025-01-28 | GH | 48.27 | 2.10 | 0.29 | 34145 |
| 2025-01-29 | GH | 47.64 | 2.08 | 0.10 | 34467 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2024-12-30 | GH | 30.55 | 20.0 | 120.4 | -2.01 |
| 2024-12-31 | GH | 30.55 | 20.0 | 121.6 | -2.01 |
| 2025-01-02 | GH | 31.76 | 20.0 | 107.6 | -2.01 |
| 2025-01-03 | GH | 33.71 | 20.0 | 99.9 | -2.01 |
| 2025-01-06 | GH | 35.91 | 20.0 | 98.8 | -2.01 |
| 2025-01-07 | GH | 36.18 | 20.0 | 118.6 | -2.01 |
| 2025-01-08 | GH | 36.59 | 20.0 | 117.3 | -2.01 |
| 2025-01-09 | GH | 36.59 | 20.0 | 121.7 | -2.01 |
| 2025-01-10 | GH | 36.70 | 20.0 | 120.6 | -2.01 |
| 2025-01-13 | GH | 38.12 | 20.0 | 107.7 | -2.01 |
| 2025-01-14 | GH | 37.48 | 20.0 | 127.6 | -2.01 |
| 2025-01-15 | GH | 37.54 | 20.0 | 120.9 | -2.01 |
| 2025-01-16 | GH | 37.34 | 20.0 | 123.2 | -2.01 |
| 2025-01-17 | GH | 36.67 | 20.0 | 127.9 | -2.01 |
| 2025-01-20 | GH | 36.66 | 20.0 | 121.7 | -2.01 |
| 2025-01-21 | GH | 45.09 | 17.6 | 38.7 | -2.01 |
| 2025-01-22 | GH | 47.17 | 17.6 | 105.1 | -2.01 |
| 2025-01-23 | GH | 48.60 | 17.6 | 110.8 | -2.01 |
| 2025-01-24 | GH | 47.18 | 17.6 | 132.4 | -2.01 |
| 2025-01-27 | GH | 46.99 | 19.7 | 123.4 | -2.01 |
| 2025-01-28 | GH | 48.26 | 19.7 | 111.7 | -2.01 |
| 2025-01-29 | GH | 47.66 | 19.7 | 126.3 | -2.01 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2024-12-30 | GH | -0.37 | 6.07 | 7.00 |
| 2024-12-31 | GH | -0.37 | 6.07 | 7.00 |
| 2025-01-02 | GH | -0.36 | 6.07 | 7.00 |
| 2025-01-03 | GH | -0.36 | 6.07 | 7.00 |
| 2025-01-06 | GH | -0.34 | 6.27 | 7.00 |
| 2025-01-07 | GH | -0.34 | 6.27 | 7.00 |
| 2025-01-08 | GH | -0.36 | 6.27 | 7.00 |
| 2025-01-09 | GH | -0.36 | 6.27 | 7.00 |
| 2025-01-10 | GH | -0.36 | 6.27 | 7.01 |
| 2025-01-13 | GH | -0.35 | 6.24 | 6.62 |
| 2025-01-14 | GH | -0.36 | 6.24 | 6.62 |
| 2025-01-15 | GH | -0.36 | 6.24 | 6.62 |
| 2025-01-16 | GH | -0.36 | 6.24 | 6.62 |
| 2025-01-17 | GH | -0.36 | 6.24 | 6.62 |
| 2025-01-20 | GH | -0.36 | 6.23 | 6.62 |
| 2025-01-21 | GH | -0.36 | 6.23 | 6.62 |
| 2025-01-22 | GH | -0.36 | 6.23 | 6.62 |
| 2025-01-23 | GH | -0.36 | 6.23 | 6.62 |
| 2025-01-24 | GH | -0.36 | 6.23 | 6.62 |
| 2025-01-27 | GH | -0.36 | 6.48 | 6.62 |
| 2025-01-28 | GH | -0.36 | 6.48 | 6.26 |
| 2025-01-29 | GH | -0.36 | 6.48 | 6.26 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.88
Avg. EPS Est. Current Quarter
-0.51
Avg. EPS Est. Next Quarter
-0.56
Insider Transactions
-0.36
Institutional Transactions
6.48
Beta
1.34
Average Sales Estimate Current Quarter
188
Average Sales Estimate Next Quarter
190
Fair Value
Quality Score
25
Growth Score
49
Sentiment Score
92
Actual DrawDown %
73.7
Max Drawdown 5-Year %
-91
Target Price
46
P/E
Forward P/E
PEG
P/S
8.5
P/B
P/Free Cash Flow
EPS
-4.24
Average EPS Est. Cur. Y
-2.01
EPS Next Y. (Est.)
-2.02
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-74.02
Relative Volume
0.71
Return on Equity vs Sector %
833.6
Return on Equity vs Industry %
842.3
EPS 1 7Days Diff
EPS 1 30Days Diff
0.01
EBIT Estimation
126.3
Guardant Health, Inc.Sector: Healthcare
Industry: Diagnostics & Research
Employees: 1768
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
stock quote shares GH – Guardant Health, Inc. Stock Price stock today
news today GH – Guardant Health, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch GH – Guardant Health, Inc. yahoo finance google finance
stock history GH – Guardant Health, Inc. invest stock market
stock prices GH premarket after hours
ticker GH fair value insiders trading